Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Spartalizumab + TNO155 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Spartalizumab | PDR001|PDR-001 | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 121 | Spartalizumab (PDR001) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (PMID: 32364844, PMID: 32179633). | |
TNO155 | TNO-155|TNO 155 | SHP2 Inhibitor 20 | TNO155 is an inhibitor of PTPN11 (SHP2), which potentially blocks SHP2 signaling, thereby inhibiting activation of the MAPK pathway and subsequent tumor cell growth (PMID: 38032104, Cancer Res (2022) 82 (12_Supplement): 1054). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04000529 | Phase I | Spartalizumab + TNO155 Ribociclib + TNO155 | Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies | Terminated | USA | ESP | DEU | BEL | AUS | 4 |